FEBRUARY 2023

MONTHLY FACTSHEET

at last valuation point in February 2023 unless otherwise stated


CCEAN EQUITY

MANAGER COMMENTARY

February saw the first monetary policy meetings for 2023 of the key central banks – the BoE, Federal Reserve and ECB. The Federal Reserve raised rates by 25bps to their highest level since 2007 and stated that inflation has eased somewhat but remains elevated. It went on to comment that while recent developments in terms of falling inflation are encouraging, it will need substantially more evidence to be confident that inflation is on a sustained downward path. In addition, the Fed has been reducing its bond portfolio via 'Quantitative Tightening' which should also act as a drag on inflation and reduce demand. Some economists think this balance sheet reduction has been the equivalent of about 2% of additional rate hikes.

In the UK the BoE raised rates by 50bps to 4% and suggested they may have peaked although the market is not so sure. Economic data remains mixed but the good news is that a recession has been avoided for now and even if it does transpire at some point in 2023 it will likely be relatively shallow. Unemployment remains low which is encouraging but business confidence, investment and productivity is weak. The government's Windsor framework in partnership with the EU should provide a modest boost to trade and business confidence.

Central banks are having to conduct a high-wire act. On the one hand they need to reduce inflation from 40-year highs whilst on the other, they want to avoid deep recessions and economic scarring. This backdrop is hardly inspiring for equity markets which fell over the month despite corporate earnings that have been broadly encouraging considering the challenging economic backdrop.



CUMULATIVE PERFORMANCE

	YTD	3MTHS	6MTHS	1YR	3YR	LAUNCH
Fund	5.41	2.77	4.74	-3.54	8.73	14.59
Benchmark	6.14	4.70	9.36	8.21	29.82	20.10
IA Sector	6.20	4.96	8.24	3.19	20.43	12.67
Rank in Sector	195/255	212/255	214/255	210/255	197/242	124/234
Quartile	4	4	4	4	4	3

Total Return, Bid to Bid, Tax UK Net, Sterling Terms. Source: T. Bailey Fund Services Limited/Financial Express Analytics. Past performance is not a reliable indicator of future results. The value of your investment and the income derived from it can go down as well as up and you may not get back the money you invested.

INVESTMENT OBJECTIVE

The Fund aims to achieve capital and income growth, and to provide a return (after fees, charges and other expenses payable out of the Fund) in excess of that of the CBOE UK All Companies Total Return Index over the long-term.

KEY DETAILS

Acc single price	114.59
Inc single price	104.58
Benchmark	CBOE UK All Co's
IA Sector	UK All Co's
Launch Date	14 May 2018
Holdings	35
Prospective yield	2.2%
Div ex dates	1/5 & 1/11
Div pay dates	30/6 & 31/12
Fund Value	£10.8 million

TOP 15 HOLDINGS

DIPLOMA	E E04
DIPLOMA	5.5%
ASHTEAD	5.3%
RELX	5.1%
DIAGEO	4.6%
UNILEVER	4.4%
JD SPORTS	4.1%
LVMH	3.9%
MICROSOFT	3.5%
DISCOVERIE	3.3%
EXPERIAN	3.1%
FERGUSON	3.1%
RECKITT BENCKISER	2.9%
WATCHES OF SWITZERLAND	2.9%
POLAR CAPITAL HOLDINGS	2.9%
CONVATEC	2.9%
TOTAL	57.5%

GEOGRAPHICAL BREAKDOWN



■ UK ■ USA ■ Europe ■ Cash



FEBRUARY 2023 FACTSHEET

COMPANY NEWS

Relx updated investors with Prelims which were robust and demonstrated the strength in depth of management, capability, and critically, future prospects. Relx has transitioned from print to digital over the last 20 years in an exemplary manner whilst maintaining a laser focus and deep understanding of their customers and their respective end markets. Revenue was up 9%, operating profit up 15%, EPS up 10%, dividend up 10%. In addition, net debt to EBITDA has fallen to 2.1x, ROIC has averaged 12.4% over the last five years and they aim to buy-back £800m of shares in 2023. We think Relx is under appreciated for the inherent quality of the business and the significant open road ahead backed with very capable management who target organic growth and bolt-on M&A. Interestingly, Relx has the ability via its unique data sets to create new markets for its customers which in turn gives their consumers better outcomes. If we look two years out the shares trade on about 20x earnings which is a significant discount to global peers such as Thomson Reuters and Verisk Analytics. We think the business is very well placed for steady growth over the medium to long-term as long as they keep executing and delivering. An analyst recently wrote that, 'We got Relx wrong...it's an even better story than we thought'.

Dechra Pharmaceuticals - global manufacturer and distributor of veterinary products - updated investors with interim results. Revenue was up 5%, operating profit up c.8%, the dividend was ahead 4% and covered 2.5x. On the other side EPS was down 20% following an equity raise to finance M&A in mid-2022. The gross margin increased 150bps but the operating margin contracted 430bps due to higher R&D to drive the pipeline of some very exciting novelty products and strategic investment into recent acquisitions. Investors were concerned by some de-stocking that took place by two US wholesalers since the year end trading update in January - interestingly this was also highlighted by peers Elanco Health and PetIQ. However, management see this as a one off as wholesalers have reduced stock holdings from 6 to 4 weeks. One of the key elements to note here is that if wholesalers drop stock levels below 4 weeks they risk not being able to reliably service their end customers - vets. Management noted they see 'sales out data' - sales the wholesalers are making to vet practices - and sales remain strong.

When taking all this into account it is important to reflect on how well the business is positioned for robust growth via a combination of organic growth and bolt-on M&A. Its record for buying and integrating businesses to drive growth has been very impressive over the years. The CEO has been in the role for over 20 years and has an excellent understanding of the industry. It has a growing competitive position and a very exciting pipeline of products to drive growth which management says is the strongest they have known. The business is well invested, trades at a discount to US peers such as Zoetis, and the growth opportunity in emerging markets such as Latin America, Eastern Europe and Asia remains compelling.



Currency

Price

MICHAEL FOSTER Lead Portfolio Manager

Michael launched the Ocean Equity Fund in May 2018. He holds the Investment Management Certificate. He has managed private investments since 2011.

JULIAN DIEPPE Co-Manager

Minimum

Julian joined the Ocean Fund at launch. He is a member of the Securities Institute and is an Investment Manager at Fiske plc. He has over 10 years of experience.



JAMES HARRISON Co-Manager

ISIN

James joined the Ocean Fund at launch. He is a Chartered Fellow of the Securities Institute and is CEO of Fiske plc. He has over 26 years of experience.

Sedol

INVESTOR PROFILE

The fund may appeal to investors who:

- C Plan to hold their investment for the long-term
- Are prepared to accept the risk C associated with the volatile nature of equity related investments
- Want total return through a blend of capital and income growth

FUND FEATURES

- Emphasis on total return (TR) via C blend of capital and dividend growth
- C Focus on quality companies with high returns on capital and strong cash flows
- C High conviction, low turnover - 'buy and manage' approach
- C 30-40 holdings
 - C Investing across the market cap universe
- Preservation of capital is paramount C over the business cycle
- C Predominantly UK and up to 20% Overseas from a listing perspective

HOW TO INVEST

Ocean Equity is available as an OEIC and is also suitable to include in stocks and shares ISAs and SIPPs.

You can buy shares in the fund by visiting: tbaileyfs.co.uk/funds/ocean-investmentfunds

Or by telephoning the Ocean Equity investor Dealing Line: 0115 988 8288 (open business days between 9am and 5pm)

Or via the following platforms:

•	
A J Bell	Interactive Investor
Aviva	Novia
Allfunds	Pershing
Aegon	7IM
Barclays	Raymond James
Charles Stanley Direct	Transact
Cofunds	Winterflood
Hargreaves Lansdown	

CONTACT US

Michael Foster (Manager) - 07771 516 565 Kevin Mordrick (Fund Sales) - 07557 798 421 100 Wood Street, London, EC2V 7AN Authorised Corporate Director & Administrator: T. Bailey Fund Services Ltd tbaileyfs.co.uk/funds/ocean-investment-funds

Annual Mgmt. *Ongoing Charge Figure Investment Charge (AMC) (OCF) - taken from capital GBP B Acc 114.59p £1,000 0.75% 1.14% GB00BDRNX587 BDRNX58 GB00BDRNX694 BDRNX69 B Inc 104.58p £1,000 0.75% 1.14%

*please note the 1.14% OCF includes the AMC Entry and Exit charges 0%

AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY | MEMBER OF THE LONDON STOCK EXCHANGE | NOT FOR DISTRIBUTION IN THE U.S.A. This factsheet has been issued by Fiske plc on the basis of publicly available information, internally developed data and other sources believed to be reliable and accurate. No representations or warranty, expressed or implied, is made nor responsibility of any kind is accepted by Fiske plc, its directors or employees either as to the accuracy or completeness of any information stated in this factsheet. Any opinions expressed (including estimates and forecasts) may be subject to change without notice. This document is not intended as an offer to buy or sell the fund nor as a personal recommendation. Fiske plc, or any of its connected or affiliated companies or their employees, may have a position or holding or other material interest in the fund concerned or in a related investment,

or may have provided within the previous twelve months, significant advice or investment services in relation to the investment concerned or a related investment. Investors must be aware of the risks associated with investment in this fund. Full details of the Ocean Equity Fund, including risk warnings, are published in the Prospectus and Key Investor Information document. The fund may not be suitable for all investors and if you are in any doubt whether the fund is suitable for you advice should be sought from a suitably auglified professional advisor. The value of the fund and the income derived from it can go down as well as up. Investors may not get back their initial investment. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realised. Securities denominated in foreign currencies may see their value fall as a result of exchange rate movements. Any comments contained in this factsheet are intended only for the use of the individual or entity to which it is addressed and may contain information which is confidential and may also be leaally privileged. If you have received this document in error, please telephone the Compliance Department on 44 (0)20-7448-4700. Fiske plc FCA Register No: 124279